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Human  pathogenic  chlamydiae  are 
members  of  a  successful  and  unique 
lineage  of  bacteria  (Collingro  et  al., 
2011), which infect and cause disease in   
a wide variety of animals (Longbottom 
and Coulter, 2003). Although anti­
biotic chemotherapy is quite effective in 
treating diagnosed primary uncompli­
cated ocular and urogenital chlamydial 
infections,  prevention  of  the  serious 
pathological sequelae, which can de­
velop after infection, and prevention 
of reinfection are much more difficult 
tasks (Byrne, 2010). Most chlamydial 
infections are asymptomatic and thus 
go undiagnosed and untreated, which 
can lead to chronic inflammation and 
irreversible tissue and organ pathology. 
In  some  countries  and  communities, 
limited access to medical care and in­
fection screening technologies further 
hampers  timely  diagnosis  and  treat­
ment  (Centers  for  Disease  Control   
and Prevention [CDC], 2011). Repeat   
infections are common, and the risk   
of developing the serious sequelae of   
ocular  (e.g.,  blindness)  or  urogenital   
infection  (e.g.,  infertility)  increases 
with multiple infections (Darville and 
Hiltke, 2010).
These obligate intracellular bacteria 
develop  within  a  membrane­bound 
vacuole termed the inclusion (Fig. 1), 
and existence within the inclusion de­
fines  much  about  the  biology  of  the 
lineage. The challenges to understanding 
and preventing chlamydial disease are 
amplified by the difficulties of work­
ing with an obligate intracellular bacte­
rial species, in which the development 
of a practical system of genetic manipu­
lation is only in its infancy. (Binet and 
Maurelli, 2009; Kari et al., 2011).
The chlamydial plasmid
In  most  microbial  systems,  autono­
mously replicating plasmids function as 
tools of genetic variation and are built 
with  replicative  backbones  associated 
with a variety of functional cassettes 
encoding niche­specific genes or gene 
sets. Often these plasmids can be hori­
zontally  transferred,  which  leads  to 
rapid distribution or reassociation of 
phenotypes among strains (Koonin et al., 
2001). The spread of antibiotic resis­
tance  is  often  a  function  of  sharing   
of  plasmids  (or  other  laterally  trans­
ferred genetic elements) among other­
wise susceptible strains. Such plasmid 
transfer is a major and evolving prob­
lem  in  infectious  disease  worldwide. 
Many serious diseases are directly the 
result of virulence factors carried by plas­
mids, and variation in plasmid structure 
is often associated with different disease 
syndromes caused by otherwise related 
strains and species.
Such  variability  is  not  found  in 
chlamydia. Several chlamydial species 
contain  one  of  a  homologous  set  of 
7,500 base pair plasmids with a copy 
number  that  is  approximately  four­
fold greater than that of the chromo­
some (Thomas et al., 1997; Pickett et al., 
2005;  Fig.  1).  Within  C.  trachomatis 
clinical isolates, the plasmid is virtually 
ubiquitous. There are occasional stud­
ies  showing  plasmid­negative  clinical 
strains, but little is known about the 
epidemiology and significance of these 
relatively rare isolates (Peterson et al., 
1990; An et al., 1992; Farencena et al., 
1997).  Chlamydial  plasmids  are  non­
conjugative and nonintegrative. They 
do  not  encode  antibiotic  resistance 
genes and do not show signs of genetic 
flexibility. This plasmid and the equally 
curious chlamydiaphage found in some 
strains  (Storey  et  al.,  1989)  represent 
the  entire  complement  of  extrachro­
mosomal  elements  carried  by  Chla-
mydia spp. There is a single example of 
an integrated plasmid in Chlamydia suis 
(Dugan et al., 2004), but this is clearly 
the exception and not the rule.
Nucleotide sequence identity among 
plasmids  from  Chlamydia  spp.  ranges 
from 69 to 99%, with very high identity 
within  C.  trachomatis  (Thomas  et  al., 
1997; Seth­Smith et al., 2009). Sequence 
comparisons  suggest  that  the  plasmids 
evolved  in  parallel  with  the  different 
chlamydial  species. The  C.  trachomatis 
plasmid carries a set of five open reading 
frames  (ORFs),  which  share  identity 
with episomal maintenance genes com­
mon to other plasmids, and a set of 
Chlamydial plasmids are small, highly conserved, nonconjugative, and non­
integrative DNA molecules that are nearly ubiquitous in many chlamydial 
species, including Chlamydia trachomatis. There has been significant recent 
progress in understanding chlamydial plasmid participation in host–microbe 
interactions, disease, and immune responses. Work in mouse model systems 
and, very recently, in nonhuman primates demonstrates that plasmid­ 
deficient chlamydial strains function as live attenuated vaccines against 
genital and ocular infections. Collectively, these studies open new avenues  
of research into developing vaccines against trachoma and sexually transmitted 
chlamydial infections.
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However, clinical isolates with a dele­
tion  in  the  target  sequence  used  in 
some diagnostic kits (the Swedish Vari­
ant) have been identified. This can lead 
to false negative test results in patients   
(Unemo  and  Clarke,  2011).  Studies 
have reported an apparent clonal expan­
sion  of  C.  trachomatis  isolates  carrying 
this deletion. It is possible that the in­
ability  to  detect  infections  caused  by 
strains carrying the deleted plasmid has 
contributed to the rapid expansion of the 
variant strains in patient populations.
As mentioned, the lack of routine 
genetic tools has been a significant bar­
rier to rapid progress in chlamydial re­
search. Manipulation of the chlamydial 
plasmid is a logical approach to intro­
duce  DNA  into  these  organisms,  but 
such  efforts  have  been  frustrating  and 
generally unproductive. However, a very 
recent study describes successful trans­
formation experiments using hybrid shut­
tle vectors built with pBR325 and the 
entire chlamydial plasmid (Wang et al., 
2011). The vectors are propagated in 
both E. coli and C. trachomatis, and the 
system was used to generate green fluor­
escent C. trachomatis. This is an exciting 
and  highly  significant  development  in 
the study of chlamydiae.
The chlamydial plasmid appears to 
be critical for growth in vivo (Russell   
et al., 2011), but it is not required for 
growth  in  vitro.  Multiple  laboratories 
have described phenotypic changes as­
sociated  with  plasmid­deficient  strains   
as compared with closely related wild 
type strains. Creation of plasmid­deficient 
isogenic strains began with the careful 
work of Akira Matsumoto, who devel­
oped a plaque­purification technique for 
chlamydial  strains  (Matsumoto  et  al., 
1998) and noted that unlike wild­type 
C. trachomatis strains, three of his plaque­
purified clones of C. trachomatis did not 
accumulate  glycogen  within  the  inclu­
sion. Each glycogen­negative clone was 
then  shown  to  lack  the  chlamydial   
plasmid. Subsequent investigations of 
plasmid­negative  strains  (O’Connell   
and Nicks, 2006; Carlson et al., 2008; 
O’Connell et al., 2011) confirmed the 
absence  of  glycogen  and  examined 
transcription  across  the  chlamydial   
genome  relative  to  wild­type  strains. 
The chlamydial plasmid also has a 
practical side. It is a common target for 
nucleic acid amplification test (NAAT)–
based  diagnostics  of  human  infections 
(Fredlund  et  al.,  2004).  NAAT­based 
tests have been, and remain, a valuable 
aspect  of  chlamydial  disease  control. 
three  genes  encoding  proteins  of   
unknown  function,  each  of  which  is 
chlamydia specific.  Human  strains  of 
Chlamydophila pneumoniae lack plasmid, 
but  equine  C.  pneumoniae  strains  and 
other veterinary chlamydial species are 
plasmid positive.
Figure 1.  Chlamydial growth and plasmid structure. The obligately intracellular chlamydiae 
develop within a host vacuole termed the inclusion. The two developmental forms have different 
functions in growth. Elementary bodies (EB) are infectious but minimally metabolically active, 
whereas reticulate bodies (RB) grow and divide, but cannot infect. As shown in a magnified reticulate 
body, the chlamydial plasmid has eight ORFs, which encode plasmid maintenance and chlamydia-
specific functions. ORF5 encodes Pgp3, which is secreted from the bacterium and the inclusion and 
accumulates in the cytosol of the host cell. Pgp3 is immunogenic in many host species. The chla-
mydial plasmid is also associated with the accumulation of glycogen granules (purple) in the lumen 
of the inclusion and, as discussed in the text, functions in virulence in animal model systems.JEM Vol. 208, No. 11 2161
Minireview
question remains unaddressed, it appears 
that some aspect of chlamydial plasmid 
biology  is  strongly  selected  for  during 
successful infection or transmission of   
the pathogen within a host population 
(Russell et al., 2011). It is likely that this 
competitive advantage tips the scale to­
ward pathogenesis in human infections. 
In addition, as repeated and/or persistent 
chlamydial infections are strongly asso­
ciated with severe pathology, it is likely 
that inflammatory responses elicited by 
the bacterium are associated with serious 
disease sequelae. Thus, the plasmid may 
encode or control expression of proteins 
that are responsible for successful bac­
terial growth and/or of the stimulation 
of a deleterious immune response. The 
search for deleterious chlamydial antigens 
has a long history, and genus­common   
antigens are thought to be major players 
in this pathogenetic response. Perhaps a 
major immunopathogenetic determinant 
is encoded by the plasmid, or the gene 
products  encoded/controlled  by  the 
plasmid allow persistence to a level that 
facilitates deleterious responses to other 
chlamydial macromolecules. Under the 
latter  model,  absence  of  the  plasmid 
would allow the bacterium to be cleared 
before an immunopathogenic response 
can be generated or amplified. Alterna­
tively, glycogen accumulation might be 
a  metabolic  equivalent  of  a  virulence 
factor, providing energy stores as chla­
mydiae fight to grow and survive in a 
hostile host environment.
Although the mechanisms of atten­
uated virulence and/or of immune pro­
tection are not clearly defined by Kari 
et al., this study is a seminal contribu­
tion to the field of chlamydia patho­
genesis and forms the basis for continued 
exploration of the role of the plasmid 
in  the  chlamydial  infectious  process. 
Future studies, perhaps encouraged by 
this  work,  will  need  to  address  the 
challenging issues of antigenic variation 
and host genetic variation in designing 
vaccine strategies.
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and it is hypothesized that Pgp3 serves   
a similar function.
Chlamydial vaccine studies are com­
plicated by the possibility that the de­
bilitating  pathology  associated  with 
chlamydial ocular and urogenital infec­
tions  represents  collateral  damage  of   
innate  and/or  adaptive  immune  re­
sponses (Rockey et al., 2009; Farris and 
Morrison, 2011). Protection, in contrast, 
is  thought  to  be  serovar  or  genovar   
specific, but neither the mechanisms of 
pathogenesis  nor  the  mechanisms  of 
protection have been clearly elucidated. 
Several candidate protective antigens have 
been explored (Rockey et al., 2009), but 
no molecule has emerged as a clear and 
practical  choice  as  a  single  protective   
antigen. Work in the mouse system sug­
gests that delivery of antigens, or a com­
bination  of  antigens,  is  required  to 
generate a protective response. Indeed,   
a live attenuated veterinary chlamydial 
vaccine, generated via chemical muta­
genesis,  is  commercially  available  and 
routinely used to reduce the incidence of 
abortion in sheep (Burall et al., 2009).
In this issue of the Journal of Experi-
mental Medicine, Kari et al. describe ex­
periments demonstrating that a plasmid­ 
deficient C. trachomatis strain is both 
avirulent  in  ocular  infections  of  ma­
caques and functions as a live attenuated 
vaccine in that system. These fascinat­
ing  studies  conclusively  demonstrate 
that the plasmid functions as a virulence 
factor in C. trachomatis ocular infections, 
consistent with the work conducted in 
the genital tract in the murine model 
system. In addition to the colonization 
studies,  Kari  et  al.  demonstrated  that 
three of the six animals infected with 
the plasmid­negative strain were com­
pletely protected against challenge by an 
isogenic  and  virulent  plasmid­positive 
strain. Analysis of the major histocom­
patibility  complex  genotypes  of  each 
animal  demonstrated  that  all  three  of 
the solidly protected animals shared a 
common  M1  haplotype,  suggesting  a 
potential role for CD4
+ T cells in the 
observed differential protection.
What role does the plasmid play in 
chlamydial infections and why is it main­
tained as an extrachromosomal element 
in  this  pathogen?  Although  the  latter 
Although the precise scope and nature of 
plasmid­chromosome cross­regulation is 
not fully understood, transcription of a 
set of chlamydial chromosomal genes is 
negatively  affected  by the absence of 
plasmid. One C. trachomatis gene that is 
down­regulated in the plasmid­negative 
strains is glgA, a glycogen biosynthetic 
gene. Thus, it is hypothesized that ele­
ments encoded by the plasmid regulate, 
and  perhaps  directly  participate  in,   
the process of glycogen accumulation 
within chlamydial inclusions.
Linking disease and vaccines  
to the chlamydial plasmid
Subsequent in vivo studies using plasmid­
deficient  strains  demonstrated  that  the 
plasmid is a virulence factor that signifi­
cantly impacts clinical disease in mouse 
model systems. For example, although 
plasmid­negative  strains  grew  similarly 
to isogenic wild­type strains, they failed to 
activate Toll­like receptor 2–dependent   
immune  responses  either  in  vivo  or   
in vitro (O’Connell et al., 2011). Other 
work indicated that plasmid­negative   
C.  trachomatis  strains  had  significantly 
higher 50% infective dose values relative 
to a wild­type matched isolate (Carlson   
et al., 2008). The plasmid­deficient strains 
also functioned as successful attenuated 
live vaccines in mice, wherein prior   
infection  with  plasmid­negative  strains 
limited the pathology associated with a 
subsequent infection by wild­type strains 
(O’Connell et al., 2007).
The near universal carriage of this 
single plasmid by C. trachomatis has led 
to speculation about its importance in 
human  chlamydial  infections.  Early 
work  demonstrated  that  chlamydia­ 
infected individuals produce antibodies 
specific for at least one plasmid­encoded 
protein,  Pgp3,  which  is  encoded  by 
ORF5 (Comanducci et al., 1994). Fur­
ther work explored the possible utility 
of Pgp3 as a vaccine candidate (Donati 
et al., 2003). Recent work has shown 
that native Pgp3 is a trimeric molecule 
that is transported to the host cell cytosol 
during the infectious process (Li et al., 
2008; Chen et al., 2010; Fig. 1). Other 
chlamydial proteins are delivered to the 
cytosol,  where  they  function  to  turn 
the host cell into a “chlamydia factory,” 2162 Emerging role for conserved chlamydial plasmids | Rockey
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